Abstract: A system for multi-factor user authentication for payment card-based transactions are described. The multifactor authentication may be based on a one-time passcode/password (OTP) as sent by an authentication server. A user device may, based on receiving the OTP, send an authentication code. The authentication code may be generated/determined based on the OTP. The authentication code may be augmented biometric identifier (ID) of a user associated with the user device. The authentication server may validate a transaction based on the authentication code.

Abstract: A compound comprising a ligand LA, having a structure of Formula I, is provided. In Formula I, A1 to A8 are each independently CR or N; at least two adjacent ones of A1 to A8 are CR and the Rs are joined together to form a six-membered ring fused to ring A or ring C; X is O, S, or Se; each R and RB is independently hydrogen or a substituent; any adjacent substituents are optionally joined or fused into a ring; the ligand LA is coordinated to a metal M; the metal M is bonded to ring A through a M-C bond; the metal M can be coordinated to other ligands; and the ligand LA is optionally linked with other ligands. Formulations, OLEDs, and consumer products containing such compounds are also disclosed.

Abstract: This invention discloses a novel two dimensional material having propellane core for organic light emitting diodes. These compounds can be used as hosts, charging transporting materials, or blocking materials for PHOLEDs. The devices comprising these compounds have better performance due to the honeycomb pi-extended structure in the propellane molecules.

Abstract: Provided are metalloorganic and organic compounds comprising a multicyclic system wherein a central nitrogen atom is part of two 5-membered rings which are fused together, and which are further fused together with three 6-membered aromatic rings. Also provided are formulations comprising these compounds. Further provided are organic light emitting devices (OLEDs) and related consumer products that utilize these compounds and compositions.

Abstract: Fluorine substituted metal complexes as efficient phosphorescent emitters is disclosed. The fluorine substitution is at para position of a phenyl group.

Abstract: A compound having the formula (LA)mIr(LB)3-m, where LA is and LB is selected from is disclosed. In the formula (LA)mIr(LB)3-m, LA and LB are different; each of X1 to X5 is C—RF or nitrogen; X is selected from O, S, and Se; each R1, R2, RB, RD, RE, and RF is hydrogen or a substituent; R3 is alkyl, cycloalkyl, or a combination thereof; and m is 1 or 2. OLEDs, consumer products, and formulations including the compound are also disclosed.

Abstract: Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.

Abstract: Provided are compounds of Formula (I?) or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R8, R9, R11A, R11B, R12, Ri, Rii, A1, A2, Q1, Q2, Q3, X, W, and n are as defined herein; pharmaceutical compositions comprising said compounds or pharmaceutically acceptable salts thereof, and pharmaceutically acceptable excipients; and methods of treating a disorder responsive to inhibition of Bruton's tyrosine kinase using said compounds, or pharmaceutically acceptable salts thereof, or said pharmaceutical compositions.

Abstract: A compound having a Pt tetradentate structure of Formula 1, is provided. In the structure of Formula 1, rings C and D each independently represent 5- or 6-membered carbocyclic or heterocyclic ring; L1, L2, and L3 are each independently a direct bond, BR, NR, PR, O, S, Se, C?O, S?O, SO2, SiRR?, GeRR?, alkyl, cycloalkyl, or a combination thereof; the sum of n1 and n2 is 1 or 2; X is selected from NRE, O, S, and Se; X3 and X4 each independently carbon or nitrogen; and one of Q1, Q3, and Q4 is oxygen, and the remaining two of Q1, Q3, and Q4 each represents a direct bond. Formulations and devices, such as an OLEDs, that include the compound of Formula 1 are also described.

Abstract: A compound having a formula (LA)mIr(LB)3?m having a structure selected from is disclosed. In the structures of formula (LA)mIr(LB)3-m, m is 1 or 2, R1, R2, R3, R4, and R5 are each independently selected from hydrogen, deuterium, C1 to C6 alkyl, C1 to C6 cycloalkyl, and partially or fully deuterated variants thereof, and partially or fully fluorinated variants thereof, and, R6 is selected from C1 to C6 alkyl, C1 to C6 cycloalkyl, and partially or fully deuterated variants thereof, and partially or fully fluorinated variants thereof.

Abstract: A novel compound selected from is disclosed.

Abstract: This application provides a cloud gaming processing method performed by a computer device, the method including: receiving an access request of a second client for a cloud gaming instance, the cloud gaming instance having been created according to a play request of a first client for a cloud gaming and shared by the first client with the second client, the first client being bound to a first stream processing resource of the cloud gaming instance, and data transmission between the cloud gaming instance and the first client being implemented by using the first stream processing resource; creating a second stream processing resource of the cloud gaming instance in response to the access request of the second client; binding the second stream processing resource to the second client; and implementing data transmission between the second client and the cloud gaming instance by using the second stream processing resource.

Abstract: The present disclosure discloses a substation frame comprising: a supporting assembly comprising at least two supporting posts arranged at intervals, the at least two supporting posts comprising one side supporting post at each end; a beam assembly comprising a beam provided between every two adjacent supporting posts; and a side wire attaching assembly provided on at least one side supporting post and positioned on a side of the side supporting post facing away from the beam.

Abstract: The present disclosure specifically discloses a substation frame, comprising: at least two supporting assemblies arranged at intervals along a first direction, at least one of the supporting assemblies comprising a first supporting part and a second supporting part that are connected to each other; and a beam assembly provided between two adjacent supporting assemblies. The first supporting part is located between the beam assembly and the second supporting part. The first supporting part is made of composite insulating material, and the second supporting part is made of metal material.

Abstract: The present invention includes a novel series of host materials for OLEDs based on substituted fused 1,2,4-triazines. The compounds of the invention may improve the device EQE and lifetime.

Abstract: Method, system, device and medium for determining a blood flow velocity in a vessel are provided. An example method includes receiving a 3D model of the vessel, which is reconstructed based on X-ray angiography images of the vessel. The method further includes specifying a segment of the 3D model by a start landmark and a termination landmark. Moreover, the method includes determining the blood flow velocity based on length of the segment and perfusion time for the segment by normalizing the blood flow velocity to correspond to a cardiac cycle. The method has a better accuracy in calculating blood flow velocity, and requires no additional modalities other than the original X-ray angiogram sequences used to visualize coronary arteries.

Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.

Abstract: Provided is a method for treating gastric cancer by blocking a CCL28 chemotactic pathway. Specifically, provided is a use of a CCL28 gene or CCL28 protein for preparing a reagent or a kit for testing gastric cancer. The gastric cancer has an abnormal up-regulated expression of both a Wnt/?-catenin signaling pathway and molecules related to CCL28 chemokine. Also provided are a testing kit, a use of a pharmaceutical composition, and a method for inhibiting the growth of cancer cells in vivo and in vitro.

Abstract: Provided are compounds of formula Ir(LA)m(LB)n, where m and n are each independently 1 or 2; and m+n=3; where LA has a structure of Formula I and LB has a structure of Formula II that are useful as emitters in OLEDs. Also provided are formulations comprising these compounds. Further provided are OLEDs and related consumer products that utilize these compounds.

Abstract: Provided are compounds of Formula (I): Formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, A1, B1, B2, Q1 and Q2 are as defined herein; and methods for their use and production.